FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088407814> ?p ?o ?g. }

• W2088407814 endingPage "2221" @default.
• W2088407814 startingPage "2221" @default.
• W2088407814 abstract "Acute kidney injury (AKI) is a serious complication of surgery and other severe health events (eg, sepsis). Its most severe form, AKI requiring dialysis, occurred during almost 164 000 hospitalizations in the United States in 2009 and was associated with almost 39 000 deaths.1 The incidence of AKI has been increasing substantially over the past decade, by 7% per year even after adjustment for changes in case mix.1 The in-hospital mortality rate associated with AKI requiring dialysis was approximately 25% for all cases, and even higher (35%) in patients undergoing cardiac surgery.1,2 In cardiac surgery, the population-attributable fraction (ie, the excess event rate or risk fraction for the outcome estimated to be potentially “attributable” to the exposure) of in-hospital mortality was almost 50% for all AKI, and 14% for AKI requiring dialysis.2 The costs associated with AKI are substantial and impose a significant burden on the health care system.3 As a consequence, numerous research efforts are under way to facilitate earlier detection and more effective prevention or treatment of AKI. However, it appears that little progress has been made because few interventions have been proven beneficial in the prevention of AKI.4 The recent Kidney Disease Improving Global Outcomes (KDIGO) AKI guidelines included numerous suggestions and recommendations for what interventions not to use, clearly indicating that “experience-based” medicine has flourished in the absence of conclusive and high-quality evidence.5 JAMA is publishing reports from 2 large clinical trials that tested a total of 3 pharmaceutical interventions for the primary or secondary prevention of AKI in patients undergoing surgery. In one report, Garg et al6 present the results from a substudy of the large Perioperative Ischemia Evaluation-2 (POISE-2) trial, which randomized 10 010 patients undergoing noncardiac surgery in a 2 × 2 factorial design to clonidine vs placebo and aspirin vs placebo. While the main trial focused on the prevention of short-term mortality and cardiovascular (myocardial infarction) risk over the first 30days following noncardiac surgery, there was substantial laboratory and preliminary clinical evidence supporting the hypotheses that either agent may also be efficacious in reducing the risk of AKI in the context of the index surgery. However, neither aspirin nor clonidine reduced the risk of AKI (13.4% for aspirin vs 12.3% for placebo; 13.0% for clonidine vs 12.7% for placebo). Moreover, aspirin use was associated with an increased risk of major bleeding, whereas clonidine was associated with an increased risk of clinically important hypotension. In another report, Bove et al7 present findings fromamulticenter, randomized,double-blind,placebo-controlled trial of fenoldopamas secondaryprevention in 667patientswhohad developedearly-stageAKI immediately following cardiac surgery. The study, which was stopped early for futility, demonstratednosignificantdifference in theprimaryoutcomeofuse of dialysis for advanced-stage AKI (69/338 [20%] patients in the fenoldopam group vs 60/329 [18%] patients in the placebo group), or in mortality at 30 days (78/338 [23%] with fenoldopamvs74/329 [22%]withplacebo). Inaddition, the rate of hypotensionwas higher with fenoldopam (26%) thanwith placebo (15%). The findings from these 2 trials demonstrated that none of the 3 interventions proved efficacious, but that all 3 exposures yielded signals towardpotential harm.These results are sobering and constitute a setback to finding effective interventions to prevent AKI and the burden of its consequences. The rationale for the use of these 3 agents (vasodilators, antiplatelet agents, anti-inflammatorydrugs)wasbasedon the presumed mediators of renal injury in the postoperative period: renal vasoconstrictionwithmedullary ischemia, inflammation, and microthrombosis. Despite the positive results shown in both animal models and small studies in humans, these large, randomizedclinical trials failed todemonstrateany benefit for the use of aspirin, clonidine, or fenoldopam. Such results raise theconcern that cliniciansand researchers arenot targeting the actual or relevantmechanisms of AKI. This lack of benefit could also be explained by the timing of the administration of studydrug, the intensity of the inflammatory cascade, or the untoward adverse effects of the specific agents. Increased rates of hypotension (clonidine, fenoldopam) and gastrointestinal bleeding (aspirin), all known precipitants of AKI, were found in patients randomized to treatment in both trials. Amongpatients experiencing these adverse effects,AKI was significantlymore common. Thus, the new evidence not only fails to demonstrate any benefit, but rather indicates net harm for each intervention tested. These outcomes are reminiscent of the experience with low-dose (“renal dose”) dopamine for thepreventionor treatment of AKI.Whereas small clinical trials suggested a benefit from infusion of low-dose dopamine, and the drug was used Related articles pages 2244 and 2254 Opinion" @default.
• W2088407814 created "2016-06-24" @default.
• W2088407814 creator A5014965271 @default.
• W2088407814 creator A5039035018 @default.
• W2088407814 date "2014-12-03" @default.
• W2088407814 modified "2023-09-26" @default.
• W2088407814 title "Prevention of Acute Kidney Injury Using Vasoactive or Antiplatelet Treatment" @default.
• W2088407814 cites W1970141770 @default.
• W2088407814 cites W1975896094 @default.
• W2088407814 cites W1983415698 @default.
• W2088407814 cites W2001457701 @default.
• W2088407814 cites W2008233785 @default.
• W2088407814 cites W2010522114 @default.
• W2088407814 cites W2023893179 @default.
• W2088407814 cites W2116365120 @default.
• W2088407814 cites W2131419242 @default.
• W2088407814 cites W2148195379 @default.
• W2088407814 cites W2165711693 @default.
• W2088407814 cites W2242506327 @default.
• W2088407814 doi "https://doi.org/10.1001/jama.2014.14548" @default.
• W2088407814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25399014" @default.
• W2088407814 hasPublicationYear "2014" @default.
• W2088407814 type Work @default.
• W2088407814 sameAs 2088407814 @default.
• W2088407814 citedByCount "12" @default.
• W2088407814 countsByYear W20884078142015 @default.
• W2088407814 countsByYear W20884078142016 @default.
• W2088407814 countsByYear W20884078142018 @default.
• W2088407814 countsByYear W20884078142019 @default.
• W2088407814 countsByYear W20884078142020 @default.
• W2088407814 countsByYear W20884078142023 @default.
• W2088407814 crossrefType "journal-article" @default.
• W2088407814 hasAuthorship W2088407814A5014965271 @default.
• W2088407814 hasAuthorship W2088407814A5039035018 @default.
• W2088407814 hasConcept C126322002 @default.
• W2088407814 hasConcept C133828647 @default.
• W2088407814 hasConcept C164705383 @default.
• W2088407814 hasConcept C177713679 @default.
• W2088407814 hasConcept C2780091579 @default.
• W2088407814 hasConcept C2780472472 @default.
• W2088407814 hasConcept C71924100 @default.
• W2088407814 hasConceptScore W2088407814C126322002 @default.
• W2088407814 hasConceptScore W2088407814C133828647 @default.
• W2088407814 hasConceptScore W2088407814C164705383 @default.
• W2088407814 hasConceptScore W2088407814C177713679 @default.
• W2088407814 hasConceptScore W2088407814C2780091579 @default.
• W2088407814 hasConceptScore W2088407814C2780472472 @default.
• W2088407814 hasConceptScore W2088407814C71924100 @default.
• W2088407814 hasIssue "21" @default.
• W2088407814 hasLocation W20884078141 @default.
• W2088407814 hasLocation W20884078142 @default.
• W2088407814 hasOpenAccess W2088407814 @default.
• W2088407814 hasPrimaryLocation W20884078141 @default.
• W2088407814 hasRelatedWork W2011347913 @default.
• W2088407814 hasRelatedWork W2049397185 @default.
• W2088407814 hasRelatedWork W2073151595 @default.
• W2088407814 hasRelatedWork W2074833529 @default.
• W2088407814 hasRelatedWork W2159512267 @default.
• W2088407814 hasRelatedWork W2304633692 @default.
• W2088407814 hasRelatedWork W2323354106 @default.
• W2088407814 hasRelatedWork W2399063111 @default.
• W2088407814 hasRelatedWork W2906311539 @default.
• W2088407814 hasRelatedWork W3119086905 @default.
• W2088407814 hasVolume "312" @default.
• W2088407814 isParatext "false" @default.
• W2088407814 isRetracted "false" @default.
• W2088407814 magId "2088407814" @default.
• W2088407814 workType "article" @default.